Endocrine

Hypoparathyroidism: management and complications

Clinical Overview and When to Suspect Hypoparathyroidism

— PTH normally mobilizes Ca²⁺ from bone, increases renal Ca²⁺ reabsorption, lowers phosphate reabsorption, and activates 1α-hydroxylase to generate calcitriol

— Loss of PTH → low ionized calcium, phosphate retention, low 1,25-(OH)₂D, hypercalciuria once replacement begins

— Transient: resolves within 6 months; permanent: persists >6 months post-op

— Autoimmune (isolated or APS type 1 with mucocutaneous candidiasis and adrenal insufficiency, AIRE mutation)

— DiGeorge syndrome (22q11.2 deletion) — pediatric presentation with cardiac defects, T-cell deficiency

— Infiltrative: hemochromatosis, Wilson disease, granulomatous, metastatic

— Radiation to neck, severe hypomagnesemia (functional hypoparathyroidism)

— Activating CaSR mutations (autosomal dominant hypocalcemia)

— Pseudohypoparathyroidism: PTH resistance, elevated PTH (key distinction)

— Perioral numbness, paresthesias, carpopedal spasm days after thyroidectomy

— Chronic fatigue, brain fog, cataracts, basal ganglia calcifications on imaging

— Seizure or QT prolongation with no obvious cause

— Refractory hypocalcemia that won't correct until Mg²⁺ is repleted

Board pearl: Always check and replete magnesium before concluding a patient has true hypoparathyroidism — hypomagnesemia both impairs PTH secretion and induces end-organ PTH resistance, mimicking the disease perfectly. Failure to do so leads to "refractory" hypocalcemia on exam stems involving alcoholics, PPI users, or diuretic patients.

Definition: Insufficient parathyroid hormone (PTH) action causing hypocalcemia + hyperphosphatemia with inappropriately low/normal PTH

Pathophysiology essentials:

Most common etiology in adults: Post-surgical (thyroidectomy, parathyroidectomy, radical neck dissection) — accounts for ~75% of cases

Other etiologies to recognize:

When to suspect on Step 3:

Presentation Patterns and Key History

— Circumoral and acral paresthesias — earliest symptom

— Muscle cramps progressing to carpopedal spasm and tetany

— Laryngospasm, bronchospasm, stridor (airway emergency)

— Seizures (generalized tonic-clonic or focal) — may occur with normal EEG between events

— Anxiety, irritability, confusion

— Neuropsychiatric: depression, cognitive slowing, "brain fog"

— Basal ganglia calcifications (Fahr syndrome pattern) → parkinsonism, dystonia, chorea

— Posterior subcapsular cataracts — classic chronic finding

— Dental: enamel hypoplasia, delayed eruption (if onset in childhood)

— Dry skin, brittle nails, alopecia, candidiasis (think APS-1)

— Nephrocalcinosis and CKD from chronic hypercalciuria during treatment

— Surgical history: thyroidectomy, parathyroidectomy, neck radiation, timing of symptoms relative to surgery

— Family history of hypocalcemia, autoimmune endocrinopathies, neck surgery

— Medications: bisphosphonates, denosumab, PPIs, loop diuretics, foscarnet, cinacalcet, citrate (massive transfusion)

— Alcohol use, malabsorption, gastric bypass (Mg and vit D loss)

— Childhood seizures, candidiasis, Addison features (APS-1 screen)

Step 3 management: In a postoperative thyroidectomy patient with perioral tingling and Ca 7.2 mg/dL, do not wait for full tetany — initiate oral calcium carbonate 1–2 g elemental q6h plus calcitriol 0.25–0.5 mcg BID, recheck calcium in 6–12 hours, and escalate to IV calcium gluconate if symptoms progress or corrected Ca <7.0 mg/dL. Always pair calcium replacement with magnesium assessment to avoid futile titration.

Acute symptomatic hypocalcemia (often post-thyroidectomy day 1–3):

Chronic hypoparathyroidism manifestations:

High-yield history questions on Step 3:

Symptom severity correlates with rate of decline, not just absolute calcium — a chronic patient may tolerate Ca 6.5 mg/dL, while a rapid drop to 7.5 post-op produces florid tetany

Physical Exam Findings and Bedside Assessment

— Chvostek sign: tapping the facial nerve ~2 cm anterior to the earlobe → ipsilateral facial twitch

— Sensitivity ~25%, specificity moderate; present in ~10% of normocalcemic adults — not pathognomonic

— Trousseau sign: BP cuff inflated 20 mmHg above systolic for 3 minutes → carpal spasm (flexed MCP, extended IP, adducted thumb)

— More specific (~94%) than Chvostek; the higher-yield Step 3 sign

— Hyperreflexia, clonus, fasciculations

— Laryngeal stridor, dyspnea, bronchospasm

— Opisthotonos, generalized seizure

— Cardiac: prolonged QT (specifically QTc), occasional torsades, decompensated heart failure in severe cases, refractory hypotension

— Posterior subcapsular cataracts on slit lamp

— Coarse, dry skin; brittle hair; transverse nail ridging

— Dental enamel defects, shortened metacarpals (consider pseudohypoparathyroidism with Albright hereditary osteodystrophy — round face, short stature, obesity, brachydactyly of 4th/5th metacarpals)

— Movement disorder (parkinsonism, chorea) from basal ganglia calcification

— Papilledema (rare): pseudotumor cerebri from chronic hypocalcemia

— Inspect neck for hematoma (airway threat)

— Voice quality (recurrent laryngeal nerve)

— Chvostek/Trousseau q4–8h for first 24h

— Continuous telemetry for QT monitoring if Ca <7.5

Key distinction: Trousseau sign carries more diagnostic weight than Chvostek. On Step 3 vignettes, a positive Trousseau + post-thyroidectomy timing essentially seals the diagnosis. A patient with shortened 4th and 5th metacarpals plus hypocalcemia plus elevated PTH points to pseudohypoparathyroidism type 1a, not true hypoparathyroidism — different management trajectory and genetic counseling implications.

Neuromuscular hyperexcitability signs (classic exam triggers):

Tetany progression to watch for:

Chronic exam clues:

Post-thyroidectomy bedside checklist:

Diagnostic Workup — Initial Labs, ECG, Imaging

— Total calcium + albumin → calculate corrected Ca: add 0.8 mg/dL per 1.0 g/dL albumin <4.0

— Ionized calcium — gold standard, especially with abnormal albumin, alkalosis, or critical illness

— Intact PTH — drawn at the same time as calcium (critical for interpretation)

— Phosphorus — typically elevated

— Magnesium — must be checked and corrected

— 25-OH vitamin D — rule out concurrent deficiency

— Creatinine/eGFR, BUN — baseline before therapy

— 24-hour urine calcium and creatinine (after stabilization) — baseline for hypercalciuria risk

— Low corrected/ionized Ca²⁺ + low or inappropriately normal PTH + high phosphate + normal Mg = primary hypoparathyroidism

— Low Ca + high PTH + high phosphate = pseudohypoparathyroidism (PTH resistance)

— Low Ca + high PTH + low phosphate = vitamin D deficiency or CKD secondary hyperparathyroidism

— Prolonged QT interval (specifically QTc) — primary worry; risk for torsades

— Diffuse T-wave changes, bradyarrhythmias

— Heart block in severe cases

— Obtain ECG on all symptomatic patients and any Ca <7.5 mg/dL

— Slit-lamp exam for cataracts

— Non-contrast head CT if neurologic symptoms — look for basal ganglia and dentate nucleus calcifications

— Renal ultrasound if longstanding disease — nephrocalcinosis, stones

— DXA scan baseline (paradoxically often high BMD in hypoparathyroidism)

Board pearl: The simultaneous draw of PTH and calcium is the diagnostic linchpin. A "normal" PTH in the face of low calcium is inappropriately normal and diagnostic of hypoparathyroidism — the gland should be maximally suppressed in only one direction (high) when calcium is low. Step 3 stems exploit this subtle interpretation error constantly.

Core diagnostic panel (order simultaneously):

Diagnostic biochemical pattern:

ECG findings:

Imaging considerations:

Diagnostic Workup — Advanced and Etiology-Specific Studies

— Detailed surgical history almost always answers it; if no surgical cause, broaden workup

— APS-1 (APECED) screen if young patient or family history:

— AIRE gene mutation testing

— 21-hydroxylase antibodies (adrenal)

— Mucocutaneous candidiasis history

— Anti-NALP5 and anti-calcium-sensing receptor antibodies (research/specialty labs)

— Concurrent autoimmune thyroid disease, vitiligo, pernicious anemia

— Family history of hypocalcemia → CASR activating mutation (autosomal dominant hypocalcemia) — important because aggressive treatment causes severe hypercalciuria/nephrocalcinosis

— Pediatric onset, congenital heart disease, abnormal facies → 22q11.2 FISH for DiGeorge

— Albright phenotype, elevated PTH → GNAS mutation analysis for pseudohypoparathyroidism 1a

— Syndromic features → consider HDR (hypoparathyroidism-deafness-renal anomalies, GATA3), Kenny-Caffey, Sanjad-Sakati

— Iron studies + ferritin (hemochromatosis)

— Ceruloplasmin, 24-h urine copper (Wilson)

— Consider neck imaging if prior radiation

— Ellsworth-Howard test (PTH infusion) to confirm PTH resistance pattern in pseudohypoparathyroidism

— 24-h urinary calcium, calcium-creatinine ratio

— Renal ultrasound

— DXA, BMD trends

— Ophthalmologic baseline

Key distinction: In autosomal dominant hypocalcemia (activating CaSR), the set-point for calcium is reset low. These patients are often asymptomatic despite Ca 7.0–7.8, and standard repletion to "normal" causes marked hypercalciuria, nephrocalcinosis, and CKD. Target Ca at the low-normal end (8.0–8.5 mg/dL) and accept residual mild hypocalcemia. Genetic confirmation changes the therapeutic ceiling — a classic Step 3 trap.

Once biochemical diagnosis is confirmed, pursue etiology:

Autoimmune evaluation:

Genetic testing indications:

Infiltrative workup if etiology unclear:

Functional testing (rare on Step 3):

Baseline studies before chronic therapy:

Risk Stratification and Management Logic

— Severe/symptomatic (tetany, seizure, laryngospasm, QTc >500, Ca <7.0 mg/dL or ionized <0.9 mmol/L): IV calcium, telemetry, ICU-level monitoring

— Mild symptomatic (paresthesias, mild cramps, Ca 7.0–8.0): oral repletion, outpatient if reliable

— Asymptomatic chronic (Ca 7.5–8.5 stable): outpatient titration of oral therapy, no IV

— Serum calcium at low-normal range (8.0–9.0 mg/dL or 2.0–2.25 mmol/L) — not mid-normal

— Phosphate within normal or slightly elevated, Ca × PO₄ product <55

— 24-hour urine calcium <300 mg (men) / <250 mg (women) or <4 mg/kg/day

— 25-OH D level >30 ng/mL

— Magnesium >2.0 mg/dL

— Symptom-free quality of life

— Without PTH, renal Ca reabsorption is impaired → exogenous Ca and calcitriol drive hypercalciuria → nephrolithiasis, nephrocalcinosis, CKD

— Avoid hypercalcemia (Ca >10.2) which markedly worsens renal injury

— Start oral elemental calcium 500–1000 mg TID–QID with meals

— Add active vitamin D (calcitriol 0.25–0.5 mcg BID) — required because 1α-hydroxylation is PTH-dependent

— Replete 25-OH D with cholecalciferol if low

— Add thiazide diuretic + low-sodium diet if hypercalciuric

— Consider PTH analog if uncontrolled despite optimization

CCS pearl: In a CCS case of post-thyroidectomy hypocalcemia, the high-yield order set is: continuous cardiac monitoring, IV access, IV calcium gluconate (if severe), serum Ca/Mg/PO₄/Cr q6h, ECG, oral calcium carbonate, calcitriol, magnesium repletion, and endocrinology consult. Don't forget to advance the clock and recheck labs — failing to repeat calcium is a common scoring loss.

Triage by severity and symptoms — not by absolute calcium alone:

Treatment goals (Endocrine Society and AACE-aligned):

Why target low-normal Ca:

Stepwise outpatient regimen build:

Pharmacotherapy — First-Line Regimens

— Calcium gluconate 1–2 g (10–20 mL of 10%) IV over 10–20 min in 50–100 mL D5W

— Follow with continuous infusion: 0.5–1.5 mg elemental Ca/kg/h (typically 11 g calcium gluconate = 990 mg elemental Ca in 1 L D5W at 50 mL/h)

— Prefer calcium gluconate over calcium chloride peripherally (chloride causes tissue necrosis with extravasation; reserve for central line / cardiac arrest)

— Recheck serum Ca q4–6h, titrate to ionized Ca >1.0 mmol/L or symptom resolution

— Always co-administer magnesium if Mg <1.8: MgSO₄ 1–2 g IV

— Calcium carbonate (40% elemental) — cheapest, take with meals (acid required for absorption)

— Avoid in patients on PPI → switch to calcium citrate (21% elemental, acid-independent, take any time)

— Daily elemental Ca dose: 1–2 g divided TID–QID (avoid single doses >500 mg — poor absorption)

— Calcitriol (1,25-OH₂D) 0.25–1.0 mcg/day divided BID — first-line active D; rapid onset, short half-life, easy to titrate

— Alternative: alfacalcidol (where available), ergocalciferol high-dose (long half-life, toxicity risk)

— Cholecalciferol 1000–2000 IU/day to maintain 25-OH D >30 ng/mL

— Hydrochlorothiazide 12.5–50 mg/day (reduces urinary Ca, but watch for hypokalemia, hyponatremia)

— Low-sodium diet (<2 g/day) — sodium drives calciuria

— Adequate hydration without excess

— Recombinant human PTH (1-84), now palopegteriparatide (TransCon PTH) — FDA-approved for chronic hypoparathyroidism inadequately controlled on standard therapy; reduces calcium/calcitriol burden, improves QoL

— Used by endocrinology; black-box osteosarcoma warning (rodent data) historically with teriparatide

Board pearl: Calcium citrate, not carbonate, in any patient on a PPI, H2 blocker, post-gastric-bypass, or with achlorhydria. Step 3 routinely embeds a PPI in the med list and expects you to switch — picking carbonate is a wrong-answer trap.

Acute severe hypocalcemia (IV therapy):

Chronic oral therapy:

Adjuncts for hypercalciuria:

Second-line / refractory:

Procedures and Refractory Management

— Refractory symptomatic hypocalcemia despite maximal oral therapy

— Recurrent hospitalizations for tetany or seizure

— Hypercalciuria with progressive CKD or nephrolithiasis on standard regimen

— Poor quality of life, cognitive dysfunction not improved by Ca normalization

— Palopegteriparatide (TransCon PTH) once-daily SC — sustained PTH levels, FDA-approved 2024 for adults

— Older agent: rhPTH(1-84) — production discontinued in US (2024)

— Teriparatide (1-34) used off-label, twice-daily SC — less physiologic

— Reduces required calcium and active vitamin D doses by ~50%

— Monitoring: Ca, PO₄, 24-h urine Ca, vitamin D, eGFR every 3–6 months

— Cryopreserved autotransplantation following parathyroidectomy

— Allotransplantation — experimental

— During thyroidectomy: identify and preserve all 4 glands, autotransplant devascularized glands into SCM or forearm

— Intraoperative PTH monitoring during parathyroidectomy

— Use of near-infrared autofluorescence imaging to identify glands

— Urology referral for symptomatic stones

— Thiazide + citrate supplementation if hypocitraturic

— Avoid loop diuretics (calciuric)

Step 3 management: A patient on 4 g elemental Ca/day + calcitriol 1 mcg BID with persistent symptoms, urine Ca 450 mg/day, and rising creatinine warrants endocrinology referral for PTH analog therapy rather than further calcium escalation. Recognize when "more calcium" is the wrong move — the kidney is failing under the load, and physiologic PTH replacement is the rational next step.

Indications for invasive or advanced management:

Recombinant PTH therapy (specialty endocrine):

Parathyroid transplantation (rare, specialized):

Surgical considerations to prevent hypoparathyroidism:

Stone/nephrocalcinosis management:

Nutrition consult for sustainable calcium/phosphate balance

Genetic counseling for inherited forms before family planning

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher baseline risk of falls and fractures — but bone density is paradoxically high in untreated hypoparathyroidism due to low bone turnover; fracture risk data mixed

— Polypharmacy: avoid concurrent loop diuretics (hypocalcemic), bisphosphonates (suppress turnover further), denosumab (precipitates severe hypocalcemia)

— Cognitive symptoms may be misattributed to dementia — always check Ca in new cognitive decline

— Drug absorption: achlorhydria common → use calcium citrate

— Cataracts may already be present from age; monitor for accelerated progression

— Phosphate retention worsens hyperphosphatemia → dietary phosphate restriction and non-calcium-based phosphate binders (sevelamer, lanthanum) preferred

— Calcitriol still effective; dose carefully, monitor closely

— Risk of vascular calcification rises with elevated Ca × PO₄ product — keep <55

— Thiazides lose efficacy at eGFR <30

— Hypercalciuria is moot at low GFR but tubular Ca handling still relevant

— Hemodialysis: dialysate calcium tailored (1.25–1.5 mmol/L)

— 25-hydroxylation impaired in severe liver disease → use calcitriol (already 1,25-active form) rather than ergocalciferol

— Coagulopathy and chronic illness may obscure tetany signs

— Loop diuretics → calciuria, hypocalcemia

— Phenytoin, phenobarbital → induce vitamin D catabolism, raise requirements

— Bisphosphonates/denosumab → contraindicated in symptomatic hypocalcemia

— Cinacalcet → contraindicated (worsens hypocalcemia)

Board pearl: A patient with osteoporosis and untreated hypoparathyroidism receiving denosumab can develop profound, life-threatening hypocalcemia within days. Always check Ca, Mg, vitamin D, and renal function before denosumab and reverse hypocalcemia first — a tested Step 3 safety scenario.

Elderly considerations:

Renal impairment (CKD):

Hepatic impairment:

Medication interactions in special populations:

Special Populations — Pregnancy, Pediatrics, and Postpartum

— Calcium requirements rise in 2nd–3rd trimester due to fetal demand and placental PTHrP

— PTHrP from placenta partially compensates → calcium and calcitriol doses often decrease in late pregnancy (counterintuitive)

— Postpartum and during lactation: PTHrP from breast tissue continues → requirements remain lower; abrupt weaning may unmask need for higher doses

— Monitor maternal ionized calcium every 3–4 weeks; adjust calcitriol/calcium

— Maternal hypercalcemia → suppresses fetal parathyroid → neonatal hypocalcemia and tetany in first week of life (warn pediatrics)

— Maternal hypocalcemia → fetal secondary hyperparathyroidism, subperiosteal bone resorption, demineralization

— Avoid thiazides in pregnancy if possible (relative contraindication; volume contraction, fetal effects)

— PTH analogs — limited safety data, generally avoided in pregnancy

— DiGeorge (22q11.2): cardiac defects (conotruncal — TOF, truncus, interrupted aortic arch), thymic aplasia → immunodeficiency, cleft palate, characteristic facies, hypocalcemia

— APS-1: triad of chronic mucocutaneous candidiasis, hypoparathyroidism, Addison disease

— Treatment with calcium and calcitriol; doses titrated by weight

— Growth, dental development, cognitive milestones must be tracked

— Avoid prolonged hypercalcemia — impairs growth and renal function

— Early (<72h): prematurity, maternal diabetes, perinatal stress

— Late (>72h): hypoparathyroidism (DiGeorge), maternal hypercalcemia, high-phosphate formula

Step 3 management: In a pregnant patient with chronic hypoparathyroidism, decrease, do not increase, calcium/calcitriol doses as PTHrP rises in late pregnancy — and rebound monitoring after weaning is critical. Counsel the pediatrician about neonatal calcium screening, particularly if maternal calcium ran high during pregnancy. Coordinate care among endocrinology, MFM, and pediatrics.

Pregnancy in hypoparathyroidism:

Pediatric hypoparathyroidism:

Neonatal hypocalcemia:

Complications and Adverse Outcomes

— Tetany, laryngospasm, seizures — acute neuromuscular

— Cardiac: prolonged QT, torsades, heart failure (reversible cardiomyopathy with severe hypocalcemia), heart block

— Basal ganglia and intracranial calcifications (Fahr-like) → parkinsonism, dystonia, chorea, cognitive impairment

— Posterior subcapsular cataracts — pathognomonic chronic finding

— Dental: enamel hypoplasia, delayed eruption, increased caries

— Pseudotumor cerebri (rare)

— Mood: depression, anxiety, reduced quality of life

— Hypercalciuria (because PTH is absent, renal Ca reabsorption fails despite normalized serum Ca) →

— Nephrolithiasis (calcium oxalate/phosphate)

— Nephrocalcinosis

— Chronic kidney disease — long-term sequela; incidence 2–17× general population

— Hypercalcemia from over-replacement — fatigue, polyuria, AKI, vascular calcification

— Hyperphosphatemia worsened by oral calcium/D dosing → soft-tissue and vascular calcification, accelerated CKD

— Ectopic calcification of vessels, kidneys, brain, eye

— Hypomagnesemia from thiazide use

— Hypokalemia/hyponatremia from thiazides

— Increased rates of renal insufficiency, neuropsychiatric disease, infection (especially in autoimmune), and cataracts

— Mortality similar to general population in most cohorts but morbidity burden is substantial

Key distinction: Hypercalciuria and nephrocalcinosis are iatrogenic, not features of the underlying disease — which is why treatment targets the low-normal calcium range. Patients told to "keep calcium normal at 9.5–10" are being mismanaged. Recognizing this on Step 3 distinguishes well-managed chronic hypoparathyroidism from preventable CKD progression and is a frequent question stem theme.

Complications of the disease itself:

Complications of treatment:

Long-term morbidity data:

When to Escalate Care — ICU, Consults, Inpatient Triage

— Symptomatic severe hypocalcemia with tetany not responsive to bolus IV calcium

— Laryngospasm or stridor

— Seizures

— QTc >500 ms or any documented ventricular arrhythmia/torsades

— Hemodynamic instability or heart failure from hypocalcemia

— Need for continuous calcium infusion with q4–6h labs

— Symptomatic patient unable to tolerate or absorb PO

— Post-thyroidectomy with falling Ca trajectory and symptoms

— New seizure or arrhythmia attributable to hypocalcemia, now stabilized

— Concomitant severe hypomagnesemia requiring IV repletion

— Refractory hypocalcemia despite calcium + calcitriol + Mg repletion

— Suspected pseudohypoparathyroidism (elevated PTH with low Ca)

— Need for PTH analog initiation

— Pregnancy with active management changes

— Newly diagnosed APS-1 or DiGeorge (multi-system coordination)

— Surgery: post-op hematoma, recurrent laryngeal nerve injury

— Nephrology: nephrocalcinosis, CKD progression, recurrent stones

— Ophthalmology: baseline and annual cataract screening

— Genetics: pediatric or familial cases

— Psychiatry: depression/anxiety not improving with biochemical control

— Asymptomatic or mild paresthesias only

— Ca >7.5 mg/dL, ionized >1.0

— QTc normal

— Reliable PO intake and follow-up

— Stable home regimen

CCS pearl: In CCS, never discharge a post-thyroidectomy patient on the same day as a dropping calcium trend without documenting at least two stable Ca values, an outpatient endocrinology follow-up within 1–2 weeks, prescribed calcium + calcitriol + a clear sick-day plan, and patient-taught Chvostek/Trousseau awareness. Premature discharge is a common CCS scoring error.

ICU admission criteria:

Inpatient (non-ICU) admission:

Emergent endocrinology consult:

Other consults:

Outpatient management criteria:

Key Differentials — Same-Category (Other Causes of Hypocalcemia)

— Low Ca, low/normal phosphate, elevated PTH (secondary hyperparathyroidism)

— Low 25-OH D; treat with cholecalciferol/ergocalciferol

— Common in elderly, dark-skinned individuals, malabsorption, anticonvulsants

— Low Ca, high phosphate, high PTH, low calcitriol

— Treat with phosphate binders, calcitriol/active D, calcimimetics (later)

— Mineral and bone disorder (CKD-MBD) — distinguish from primary hypoPT by PTH and renal function

— Low Ca, high phosphate, markedly elevated PTH

— Type 1a: GNAS maternal allele mutation, Albright hereditary osteodystrophy phenotype (short stature, round face, short 4th/5th metacarpals, obesity, intellectual disability)

— Type 1b: renal-only resistance, normal phenotype

— Treat similarly with calcium and active vitamin D, but PTH cannot be normalized

— Mg <1.0 mg/dL impairs PTH secretion and induces end-organ PTH resistance

— Functional hypoparathyroidism — PTH is low or low-normal despite hypocalcemia

— Causes: alcohol, PPIs, loop diuretics, aminoglycosides, cisplatin, malabsorption, refeeding

— Reverses with magnesium repletion

— Post-parathyroidectomy in patients with severe preop hyperparathyroidism

— Rapid Ca uptake into bone → low Ca, low PO₄, low Mg, PTH low-normal post-op then recovers

— Treat with aggressive Ca, calcitriol, Mg

Key distinction: The PTH level differentiates the major categories. Low PTH + low Ca = true hypoparathyroidism (or functional, via Mg). High PTH + low Ca = vitamin D deficiency, CKD, or pseudohypoparathyroidism (resistance). This single lab interpretation is tested repeatedly.

Vitamin D deficiency or insufficiency:

Chronic kidney disease (secondary hyperparathyroidism):

Pseudohypoparathyroidism (PTH resistance):

Hypomagnesemia-induced hypocalcemia:

Hungry bone syndrome:

Acute pancreatitis, sepsis, rhabdomyolysis, tumor lysis — sequestration/precipitation of calcium

Massive transfusion (citrate chelation), foscarnet, bisphosphonates, denosumab

Key Differentials — Other-Category Mimics

— Perioral and digital paresthesias from hyperventilation-induced respiratory alkalosis mimic hypocalcemic tetany

— Mechanism: alkalosis lowers ionized calcium (more bound to albumin) without changing total Ca

— Differentiator: normal corrected and ionized Ca on ABG with simultaneous Ca level; symptoms resolve with rebreathing

— Trousseau may even be positive transiently during hyperventilation

— Epilepsy, drug withdrawal seizures (alcohol, benzo), CNS infection

— Always check Ca, Mg, Na, glucose in any first-time or breakthrough seizure

— Parkinson disease, Huntington, Wilson — overlap with chronic hypoparathyroidism's basal ganglia calcifications

— Head CT + Ca level distinguishes

— Congenital LQTS (KCNQ1, KCNH2, SCN5A) vs acquired (drugs, electrolyte)

— Acquired causes overlap: hypocalcemia, hypokalemia, hypomagnesemia, QT-prolonging drugs (macrolides, fluoroquinolones, ondansetron, methadone, antipsychotics)

— Check full electrolyte panel and med list before assuming congenital

— Hyponatremia, hypokalemia, hypomagnesemia (without hypocalcemia)

— Statin myopathy

— Hypothyroidism

— Peripheral neuropathy

— Hypoparathyroidism, diabetes, steroid use, atopic dermatitis, congenital, trauma, radiation

— Posterior subcapsular pattern + hypocalcemia narrows it

— Hypoparathyroidism, vitamin D-resistant rickets, amelogenesis imperfecta, fluorosis, celiac disease

Board pearl: When a young woman presents to the ED with perioral tingling, carpopedal spasm, and a positive Trousseau after an anxiety-provoking event, do not stop at "panic attack" — check ionized calcium and an ABG. Acute respiratory alkalosis from hyperventilation lowers ionized Ca transiently and produces real, not imagined, tetany. Treatment is rebreathing and reassurance, not IV calcium.

Anxiety/panic disorder:

Seizure disorders unrelated to calcium:

Movement disorders:

Long QT syndromes:

Muscle cramps from other causes:

Cataracts in younger patients:

Dental enamel defects in children:

Secondary Prevention, Discharge, and Long-Term Plan

— Elemental calcium 1–2 g/day divided TID–QID (carbonate with meals or citrate any time)

— Calcitriol 0.25–0.5 mcg BID (titrate)

— Cholecalciferol 1000–2000 IU/day to maintain 25-OH D >30

— Magnesium oxide 400 mg daily if hypomagnesemia history or PPI use

— Thiazide (HCTZ 12.5–25 mg/day) if hypercalciuric

— Avoid: loop diuretics, bisphosphonates, denosumab without endocrinology guidance

— Vomiting/diarrhea/poor PO intake → take extra calcium, hydrate, call provider

— Worsening paresthesias, cramps, confusion → ED for IV calcium

— Carry a medical alert bracelet/card stating "hypoparathyroidism — IV calcium needed if symptomatic"

— Adequate dairy/calcium-rich foods

— Low-sodium diet (reduces calciuria)

— Adequate hydration (2–2.5 L/day in healthy renal function)

— Limit phosphate-heavy processed foods and cola if hyperphosphatemic

— Avoid alcohol excess (worsens Mg)

— Influenza annually, COVID boosters per current guidance, pneumococcal series

— Maintain Ca 8.0–9.0 mg/dL — low-normal, not mid-normal

— 24-h urine Ca <250–300 mg

— Phosphate within or near normal

— Avoid CKD progression, nephrolithiasis, cataracts, mood symptoms

— Before any new prescription (especially PPI, loop, bisphosphonate, denosumab, anticonvulsant) — reconcile calcium impact

Step 3 management: Build the discharge bundle as a package: calcium + calcitriol + vitamin D + lifestyle + sick-day plan + alert bracelet + 2-week follow-up labs + endocrine appointment within 4 weeks. Missing the sick-day education or medical alert recommendation is a common QI/safety-flavored test answer.

Discharge medication checklist:

Sick-day rules (teach the patient):

Lifestyle and dietary counseling:

Vaccination and infection prevention especially if APS-1 (chronic candidiasis, adrenal):

Long-term goals:

Drug stewardship:

Follow-Up, Monitoring, and Counseling

— First 1–2 weeks post-discharge: corrected Ca, Mg, phosphate, creatinine

— Every 2–4 weeks during dose titration

— Every 3–6 months once stable: Ca, Mg, PO₄, Cr, 25-OH D, 24-hour urine Ca and Cr

— Annual: urine Ca, renal ultrasound (every 2–5 years or sooner if stones), DXA scan

— Annual: slit-lamp ophthalmologic exam for cataracts

— Brain imaging only if neurologic symptoms emerge (not routine)

— Ca 8.0–9.0 mg/dL

— PO₄ within normal range

— Mg >2.0

— Ca × PO₄ <55

— 24-h urine Ca <250 (women) / <300 (men) mg or <4 mg/kg

— Stable eGFR

— Symptom freedom

— Persistent hypocalcemia → increase calcitriol first (faster onset than calcium dose adjustments)

— Hypercalciuria → reduce calcium dose, add thiazide, low-sodium diet

— Hyperphosphatemia → reduce calcium with meals, dietary phosphate restriction, consider non-Ca phosphate binder

— Rising creatinine → ultrasound, urinalysis, reduce calcium target, consider PTH analog referral

— Recognize tetany prodrome (perioral tingling, cramps)

— Avoid OTC bisphosphonate-containing remedies, herbal Ca supplements not counted

— Drug-drug interactions and PPI conflicts

— Pregnancy planning — preconception counseling

— Mental health: screen for depression/anxiety annually (high prevalence)

— Adherence is the dominant determinant of long-term outcomes

CCS pearl: Schedule the follow-up before the case ends: "Endocrinology in 2 weeks, primary care in 1 month, labs in 1 week (Ca, Mg, PO₄, Cr), ophthalmology baseline, 24-h urine Ca in 1 month." CCS rewards explicit longitudinal planning; failing to set follow-up loses points even with otherwise perfect inpatient management.

Outpatient lab monitoring cadence:

Targets to confirm at each visit:

Adjusting therapy:

Patient education topics:

Ethical, Legal, and Patient Safety Considerations

— Must explicitly discuss risk of permanent hypoparathyroidism (~1–3% experienced surgeons, higher for re-operations or extensive neck dissection)

— Disclose recurrent laryngeal nerve injury, hematoma, and lifetime medication need

— Failure to disclose permanent hypoparathyroidism risk is a recognized malpractice exposure

— Post-thyroidectomy patients discharged before calcium nadir (typically 24–72h post-op) — institute standardized discharge protocols with prophylactic calcium/calcitriol or postoperative PTH-guided risk stratification

— Medication reconciliation at every transition — a new PPI prescribed by a covering physician can derail calcium absorption

— Communication to PCP: hand-off note must specify lifelong therapy, target Ca, monitoring plan

— Denosumab in undiagnosed hypoparathyroidism → severe, sometimes fatal hypocalcemia; FDA boxed warning emphasizes pre-administration Ca check

— IV calcium chloride extravasation → tissue necrosis; protocol: gluconate peripherally

— Vitamin D toxicity from over-supplementation — chronic hypercalcemia, AKI

— Discuss heritability (autosomal dominant CaSR, DiGeorge, GNAS) before conception

— Coordinate fetal monitoring; explain neonatal calcium surveillance need

— Adverse drug events (denosumab-induced hypocalcemia) reportable to FDA MedWatch

— Surgical complication rates often part of hospital quality metrics

— Lifelong daily medication burden; cognitive impairment from chronic hypocalcemia can ironically impair adherence — assess capacity, involve caregivers

— Cost: calcitriol can be expensive; check insurance coverage, use patient assistance programs

Board pearl: A patient presenting to the ED in tetany after a covering oncologist gave denosumab without checking calcium is a classic patient-safety vignette: the correct answer is "implement a pre-denosumab calcium/vitamin D verification protocol" — a systems-level, not individual-blame, response.

Informed consent for thyroid/parathyroid surgery:

Transition-of-care risks (Step 3 high-yield):

Drug safety events:

Pregnancy ethics and counseling:

Mandatory reporting and quality:

Capacity and adherence:

High-Yield Associations and Rapid-Fire Facts

— Post-thyroidectomy + perioral tingling + Trousseau = acute hypoparathyroidism

— Hypocalcemia + high PTH + Albright phenotype = pseudohypoparathyroidism 1a

— Hypocalcemia + cardiac defect + thymic aplasia = DiGeorge (22q11.2)

— Mucocutaneous candidiasis + hypoparathyroidism + Addison = APS-1 (APECED, AIRE)

— Refractory hypocalcemia in alcoholic = hypomagnesemia

— Hypocalcemia + basal ganglia calcifications = chronic hypoparathyroidism (Fahr-like)

— Posterior subcapsular cataract in young adult = chronic hypocalcemia

— Hypocalcemia + nephrocalcinosis + activating CaSR = autosomal dominant hypocalcemia

— Massive transfusion + tetany = citrate-induced hypocalcemia

— Corrected Ca = measured Ca + 0.8 × (4 − albumin)

— Calcium gluconate 10% = 93 mg elemental Ca per 10 mL

— Calcium chloride 10% = 273 mg elemental Ca per 10 mL (central line preferred)

— Calcium carbonate = 40% elemental

— Calcium citrate = 21% elemental

— Target serum Ca: 8.0–9.0 mg/dL

— Target urine Ca: <250 (♀) / <300 (♂) mg/24h

— Ca × PO₄ product <55

— QTc concern: >450 (♂) / >470 (♀); torsade risk >500

— PPI → reduced calcium carbonate absorption → use citrate

— Loop diuretic → calciuria → worsens hypocalcemia

— Thiazide → reduces calciuria → adjunct in hypoparathyroidism

— Phenytoin/phenobarbital/rifampin → induce CYP, accelerate vitamin D catabolism

— Bisphosphonates, denosumab → severe hypocalcemia risk

— Cinacalcet → contraindicated (worsens hypocalcemia)

— APS-1: CHAMP (Candidiasis, Hypoparathyroidism, Addison, Mucocutaneous, AIRE-mediated, Pernicious anemia/other)

— DiGeorge: CATCH-22 (Cardiac, Abnormal facies, Thymic aplasia, Cleft palate, Hypocalcemia, 22q11)

Key distinction: PTH low or inappropriately normal in the face of hypocalcemia distinguishes hypoparathyroidism from every other cause of low calcium. Memorize this single interpretive rule and most differential questions resolve in one step.

Buzzword pairings:

Numbers worth memorizing:

Drug-disease quick hits:

Genetic mnemonics:

Board Question Stem Patterns

— Day 1 post-thyroidectomy patient with perioral tingling and carpal spasm; Ca 7.0, PTH low, Mg 2.0

— Answer: IV calcium gluconate; start oral Ca + calcitriol; monitor; outpatient endocrine follow-up

— Chronic alcohol, on PPI, Ca 7.2 doesn't correct with IV Ca alone

— Answer: Replete magnesium — functional hypoparathyroidism

— Short stature, round face, short 4th/5th metacarpals, low Ca, high PTH, high phosphate

— Answer: Pseudohypoparathyroidism type 1a, GNAS mutation

— Elderly woman with osteoporosis given denosumab without Ca check; develops tetany 5 days later

— Answer: Safety question — pre-administration calcium/vitamin D screening protocol

— Teenager with recurrent oral candidiasis, hypocalcemia, hyperpigmentation, hyponatremia

— Answer: APS-1; check 21-hydroxylase antibodies, AIRE

— Hypoparathyroid patient on Ca 3 g + calcitriol with rising creatinine, urine Ca 500, kidney stones

— Answer: Reduce Ca target to low-normal, add thiazide + low-sodium diet, consider PTH analog

— Known hypoparathyroid woman, 30 weeks pregnant, Ca rising on stable dose

— Answer: Decrease calcitriol/calcium dose (PTHrP from placenta)

— Newborn with seizures, hypocalcemia, truncus arteriosus, absent thymus on CXR

— Answer: 22q11.2 FISH; calcium + calcitriol; immune workup; cardiac surgery

— Patient on azithromycin develops QT 540, hypocalcemia, torsades

— Answer: IV magnesium + calcium; stop offending drug

— Patient with cognitive complaints, CT shows bilateral basal ganglia calcifications

— Answer: Check Ca, PO₄, PTH — chronic hypoparathyroidism

Step 3 management: Across all stems, the decision tree is: (1) confirm hypocalcemia with corrected/ionized Ca, (2) check Mg simultaneously, (3) interpret PTH to localize cause, (4) treat acutely if symptomatic, (5) initiate or adjust chronic therapy with low-normal Ca target, (6) plan follow-up, monitor urine Ca and renal function, (7) educate on sick-day rules and medical alert.

Pattern 1 — Postoperative tetany:

Pattern 2 — Refractory hypocalcemia in alcoholic:

Pattern 3 — Albright phenotype child:

Pattern 4 — Denosumab disaster:

Pattern 5 — APS-1 vignette:

Pattern 6 — Hypercalciuria iatrogenic:

Pattern 7 — Pregnancy adjustment:

Pattern 8 — DiGeorge neonate:

Pattern 9 — Long QT with tetany:

Pattern 10 — Brain imaging incidental:

One-Line Recap

Hypoparathyroidism is the syndrome of low calcium with inappropriately low PTH — treat it acutely with IV/PO calcium plus active vitamin D (calcitriol), always replete magnesium first, target serum calcium in the low-normal range (8.0–9.0 mg/dL) to minimize hypercalciuria-driven nephrolithiasis and CKD, and arrange longitudinal monitoring of serum/urine calcium, phosphate, renal function, and cataract screening.

Board pearl: If you remember nothing else — low calcium + low PTH = hypoparathyroidism, treat low-normal not normal-normal, and check magnesium before declaring failure. That single sentence answers most Step 3 vignettes on this topic.

Diagnostic shortcut: Low Ca + low/inappropriately normal PTH + high PO₄ + normal Mg = hypoparathyroidism. High PTH instead = vitamin D deficiency, CKD, or pseudohypoparathyroidism (resistance).

Acute management: IV calcium gluconate (not chloride peripherally) for symptomatic Ca <7.0, tetany, seizure, QTc >500, or laryngospasm; always co-replete magnesium; start oral calcium + calcitriol bridge.

Chronic management priorities: Calcium 1–2 g elemental/day (citrate if on PPI), calcitriol 0.25–1 mcg/day, cholecalciferol to keep 25-OH D >30, thiazide + low-sodium diet for hypercalciuria, PTH analog (palopegteriparatide) if refractory.

Special-population landmines: Pregnancy lowers requirements (placental PTHrP); denosumab/bisphosphonates can trigger life-threatening hypocalcemia — always pre-check Ca; in CKD use non-calcium phosphate binders; in autosomal dominant hypocalcemia (CaSR-activating), accept Ca 8.0 because aggressive repletion destroys kidneys.